Comparative Pharmacology
Head-to-head clinical analysis: ITRACONAZOLE versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ITRACONAZOLE versus POSFREA.
ITRACONAZOLE vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
200 mg orally once daily; for life-threatening infections, can be increased to 200 mg three times daily for first 3 days then twice daily. IV: 200 mg IV every 12 hours for 2 days, then 200 mg IV once daily.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Terminal elimination half-life of itraconazole is approximately 24-36 hours after a single dose, but upon chronic dosing, the half-life increases to 34-42 hours due to saturable metabolism. For the active metabolite hydroxyitraconazole, half-life is similar. This prolonged half-life supports once- or twice-daily dosing.
Clinical Note
moderateItraconazole + Tranilast
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast."
Clinical Note
moderateItraconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tolfenamic acid."
Clinical Note
moderateItraconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide."
Clinical Note
moderate12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Itraconazole is extensively metabolized in the liver; the primary route of elimination is fecal (approximately 54% as metabolites, 18% as unchanged drug). Renal excretion accounts for about 35% of the dose, with <1% as unchanged drug. Bilary excretion also contributes.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category D/X
Category C
Azole Antifungal
Azole Antifungal
Itraconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronic acid."